Masimo Partners with March of Dimes to Help Parents with Babies in the NICU Make the Transition from Hospital to Home
Masimo (NASDAQ: MASI) and March of Dimes are partnering to support parents with babies in the Neonatal Intensive Care Unit (NICU). Masimo will donate $100,000 worth of Stork™ Smart Home Baby Monitoring Systems to families in need through March of Dimes' NICU Family Support program. The partnership aims to assist over 50,000 families nationwide as they transition from hospital to home.
Stork, an FDA-cleared monitoring system, uses Masimo SET® sensor technology to track a baby's oxygen saturation, pulse rate, and skin temperature. The collaboration will include NICU Awareness Month programs, donation matching events, and educational video releases. This initiative addresses the needs of the 9-13% of babies requiring NICU stays due to complex medical needs.
Masimo (NASDAQ: MASI) e March of Dimes stanno collaborando per supportare i genitori con neonati in Terapia Intensiva Neonatale (TIN). Masimo donerà 100.000 dollari di sistemi di monitoraggio per baby room Stork™ Smart Home alle famiglie bisognose attraverso il programma di supporto per le famiglie della TIN di March of Dimes. L'obiettivo della partnership è assistere oltre 50.000 famiglie a livello nazionale nel passaggio dall'ospedale alla casa.
Stork, un sistema di monitoraggio approvato dalla FDA, utilizza la tecnologia del sensore Masimo SET® per monitorare la saturazione di ossigeno, la frequenza cardiaca e la temperatura della pelle del bambino. La collaborazione includerà programmi per il mese della consapevolezza sulla TIN, eventi di abbinamento delle donazioni e rilascio di video informativi. Questa iniziativa affronta le esigenze del 9-13% di neonati che necessitano di rimanere in TIN a causa di complesse esigenze mediche.
Masimo (NASDAQ: MASI) y March of Dimes se están asociando para apoyar a los padres con bebés en la Unidad de Cuidados Intensivos Neonatales (UCIN). Masimo donará 100,000 dólares en sistemas de monitoreo para el hogar Stork™ Smart Home a familias necesitadas a través del programa de apoyo familiar de UCIN de March of Dimes. La asociación tiene como objetivo ayudar a más de 50,000 familias en todo el país durante la transición del hospital a casa.
Stork, un sistema de monitoreo aprobado por la FDA, utiliza la tecnología de sensor Masimo SET® para rastrear la saturación de oxígeno, la frecuencia del pulso y la temperatura de la piel del bebé. La colaboración incluirá programas del Mes de Concienciación sobre la UCIN, eventos de igualación de donaciones y lanzamientos de videos educativos. Esta iniciativa aborda las necesidades del 9-13% de los bebés que requieren estancias en la UCIN debido a complejas necesidades médicas.
Masimo (NASDAQ: MASI)와 March of Dimes가 신생아 집중 치료실(NICU)에서 아기를 둔 부모를 지원하기 위해 협력하고 있습니다. Masimo는 March of Dimes의 NICU 가족 지원 프로그램을 통해 어려움을 겪고 있는 가족에게 100,000달러 상당의 Stork™ 스마트 홈 아기 모니터링 시스템을 기부합니다. 이 파트너십은 병원에서 집으로 옮겨가는 과정에서 50,000명 이상의 가족을 지원하는 것을 목표로 하고 있습니다.
FDA 승인을 받은 Stork는 Masimo SET® 센서 기술을 사용하여 아기의 산소 포화도, 맥박 수 및 피부 온도를 추적합니다. 이번 협력에는 NICU 인식의 달 프로그램, 기부 매칭 이벤트 및 교육 비디오 출시가 포함될 것입니다. 이 이니셔티브는 복잡한 의료 요구로 인해 NICU에 머물러야 하는 아기의 9-13%의 필요를 다루고 있습니다.
Masimo (NASDAQ: MASI) et March of Dimes s'unissent pour soutenir les parents de bébés en unité de soins intensifs néonatals (USIN). Masimo fera don de 100 000 dollars en systèmes de surveillance domestique Stork™ Smart Home aux familles dans le besoin, par le biais du programme de soutien aux familles de l'USIN de March of Dimes. Le partenariat vise à aider plus de 50 000 familles à travers le pays dans leur transition de l'hôpital à la maison.
Stork, un système de surveillance approuvé par la FDA, utilise la technologie de capteur Masimo SET® pour suivre la saturation en oxygène, le rythme cardiaque et la température de la peau d'un bébé. La collaboration comprendra des programmes pour le mois de sensibilisation à l'USIN, des événements de mise en correspondance des dons et la diffusion de vidéos éducatives. Cette initiative répond aux besoins des 9-13% des bébés nécessitant un séjour en USIN en raison de besoins médicaux complexes.
Masimo (NASDAQ: MASI) und March of Dimes arbeiten zusammen, um Eltern mit Säuglingen auf der Neonatal-Intensivstation (NICU) zu unterstützen. Masimo wird 100.000 Dollar in Form von Stork™ Smart Home Baby Monitoring-Systemen an bedürftige Familien über das NICU Familienunterstützungsprogramm von March of Dimes spenden. Das Ziel der Partnerschaft ist es, über 50.000 Familien landesweit bei ihrem Übergang vom Krankenhaus nach Hause zu helfen.
Stork, ein von der FDA zugelassenes Überwachungssystem, verwendet die Masimo SET® Sensortechnologie, um die Sauerstoffsättigung, die Herzfrequenz und die Hauttemperatur eines Babys zu überwachen. Die Zusammenarbeit umfasst Programme zum Monat des Bewusstseins für NICU, Spenden-Equalizing-Veranstaltungen und die Veröffentlichung von Schulungsvideos. Diese Initiative befasst sich mit den Bedürfnissen von 9-13% der Babys, die aufgrund komplexer medizinischer Bedürfnisse in der NICU bleiben müssen.
- Partnership with March of Dimes expands Masimo's market reach in the baby monitoring segment
- Donation of $100,000 worth of Stork™ systems may lead to increased brand awareness and potential future sales
- Collaboration with a reputable non-profit organization could enhance Masimo's corporate image and social responsibility profile
- None.
Insights
Masimo's partnership with March of Dimes represents a significant step in supporting NICU families. The donation of $100,000 worth of Stork™ Smart Home Baby Monitoring Systems is substantial, but its impact goes beyond monetary value. This technology, leveraging Masimo SET® pulse oximetry, could potentially improve post-NICU care outcomes.
The Stork system's ability to monitor oxygen saturation, pulse rate and skin temperature in neonates at home is a game-changer. It addresses a critical gap in care transition from hospital to home, potentially reducing readmission rates and parental anxiety. However, it's important to note that while beneficial, home monitoring should not replace professional medical care.
This partnership could lead to valuable data collection on post-NICU infant health, potentially informing future neonatal care practices. Overall, this initiative shows promise in improving neonatal health outcomes and supporting new parents during a challenging transition period.
While the
The partnership aligns with Masimo's strategy to expand into the consumer health market, diversifying revenue streams beyond hospital settings. If successful, this could positively impact Masimo's financial performance in the coming years. However, investors should note that the consumer health market is highly competitive and success is not guaranteed.
While this news is positive for Masimo's image, its immediate financial impact is likely minimal. Long-term investors should monitor how this partnership translates into consumer adoption of Masimo's home monitoring technology and its effect on revenue growth in the consumer segment.
This partnership positions Masimo strategically in the growing home healthcare market, estimated to reach
The collaboration with March of Dimes, a respected non-profit, enhances Masimo's credibility in the consumer space. This could be important as Masimo competes with established consumer electronics brands entering the health tech market. The partnership also provides valuable direct access to the target demographic through March of Dimes' NICU Family Support program.
However, success will depend on product efficacy, user experience and pricing strategy. Masimo must balance premium positioning with affordability to capture a significant market share. The company should also prepare for potential regulatory challenges as home health monitoring devices face increasing scrutiny.
Company to Donate
(Photo: Business Wire)
As part of the partnership, Masimo is committed to donating
“Going home is an exciting and long hoped for milestone for new parents, but it is often one of the most overwhelming times for NICU families. Stork, which is powered by the same Masimo SET® sensor technology that’s been trusted in NICUs for decades, was developed to help parents have more peace of mind by keeping them informed about their baby’s health when caring for them at home,” said Joe Kiani, Founder and CEO of Masimo. “Together with March of Dimes and their premier NICU Family Support program, we aim to improve health outcomes for the youngest and most vulnerable patients and provide additional support to new parents as they bring their little ones home from the hospital.”
Stork leverages the same Masimo SET® pulse oximetry technology developed over 35 years ago and is the only device with over-the-counter FDA clearance for use on neonates the day they come home*. Stork monitors a baby’s oxygen saturation level (SpO2), pulse rate (PR), and skin temperature, and notifies caregivers with visual and audible alarms if a baby’s SpO2 or PR readings fall outside of preset ranges.
"March of Dimes is pleased to announce our partnership with Masimo Stork – a collaboration rooted in our mutual commitment to empowering NICU families through knowledge, compassion, and support,” said Kara Gilardi, Associate Vice President, March of Dimes NICU Family Support. “Stork’s sponsorship will support the evidence-based programs we provide that make a world of difference for families in the NICU and the providers who care for them.”
The partnership will also feature key activation moments throughout 2024 and 2025, including NICU Awareness Month programs, donation matching events highlighting Masimo's commitment to supporting families of NICU babies, and video releases that honor NICU families and provide vital resources to assist them in their transition home.
For more information, please visit MasimoStork.com/MOD.
*Masimo Stork is 510(k) cleared for OTC use as a wearable device intended for the monitoring of multiple physiological parameters. Masimo Stork is indicated for spot-checking and continuous monitoring of SpO2 and PR during no motion, motion, and low perfusion conditions in infants and neonates who are 0 to 18 months of age and between 6 and 30 lbs. Masimo Stork OTC is also indicated for continuous skin temperature measurements of infants and neonates who are 0 to 18 months of age and between 6 and 30 lbs. Masimo Stork is indicated for use in home environments.
@Masimo | #Masimo
About March of Dimes
March of Dimes leads the fight for the health of all moms and babies. We provide research, education, advocacy, and to give every family the best possible start. Since 1938, we’ve built a successful legacy to support every pregnant person and every family. Visit marchofdimes.org or nacersano.org for more information.
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.2 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,3 improve CCHD screening in newborns,4 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.5-8 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,9 and is the primary pulse oximetry at all 10 top
References
- https://nyulangone.org/news/born-just-1-pound-baby-named-battle-thriving-after-167-days-nicu
- Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
- As ranked in the 2024 Newsweek World's Best Hospitals listing, available here.
Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo Stork® and Masimo SET, as well as Masimo’s partnership with March of Dimes (the “Partnership”). These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo Stork and Masimo SET, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks that the Partnership fails to support March of Dimes’ NICU Family Support® program or feature key activation moments as mentioned in this press release; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827688455/en/
Media Contact:
Masimo
Matt Whewell
720-838-0691
matt.whewell@masimo.com
March of Dimes
Sarah Smith
571-257-3003
ssmith@marchofdimes.org
Source: Masimo
FAQ
What is Masimo's new partnership with March of Dimes for NICU babies?
How many families will Masimo's partnership with March of Dimes support?
What does the Masimo Stork™ monitoring system measure for babies?
When is Masimo's partnership with March of Dimes scheduled to take place?
